January 2023

Re: Insuman® (human insulin) range discontinuation

Dear Healthcare Professional,

I am writing to inform you of the discontinuation of the remaining presentations of Insuman® insulin in the UK, listed below. This discontinuation is **not** due to any safety concerns.

1. **Insuman® Basal 100 IU/ml suspension for injection in a cartridge (Insulin isophane human)**
   Expected End of Supply: June 2023

2. **Insuman® Basal SoloStar 100 IU/ml suspension for injection in a pre-filled pen (Insulin isophane human)**
   Expected End of Supply: June 2023

3. **Insuman® Comb 25 100 IU/ml suspension for injection in a cartridge (Insulin biphasic isophane human)**
   Expected End of Supply: May 2023

4. **Insuman® Comb 25 SoloStar 100 IU/ml suspension for injection in a pre-filled pen (Insulin biphasic isophane human)**
   Expected End of Supply: June 2023

5. **Insuman® Rapid 100 IU/ml solution for injection in a cartridge (Insulin soluble human)**
   Expected End of Supply: May 2023

Expected end supply dates are only approximate and supply may be exhausted before/after these dates based on future patient demand.

Background:
Demand for Insuman® regular human, isophane and isophane pre-mixed insulins in the UK has declined significantly in recent years. Today, fewer than 1% of people receiving insulin in the UK are prescribed Insuman® regular human, isophane or isophane pre-mixed insulins, as people with diabetes are increasingly managed with modern analogue insulins. Furthermore, fewer than 3% of people prescribed a human insulin in the UK are prescribed Insuman® regular human, isophane or isophane pre-mixed insulins.[1]

The decision has therefore been taken to discontinue the remaining presentations of Insuman® regular human, isophane and isophane pre-mixed insulins in the UK, phased over the next 6 months as outlined above.

Please note that no other Sanofi insulins are impacted by this decision.

Registered in England and Wales as Aventis Pharma Limited Company No. 01535640 ▪ T: 01183 543 000 ▪ F: 0800 471 8627
Registered Office: 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
www.sanofi.co.uk

The Department of Health and Social Care (DHSC) has been informed of this decision and Sanofi wanted to communicate this to you at the earliest opportunity, to afford you the necessary time to make decisions regarding ongoing treatment for your patients.

Next steps:
If you have patients currently receiving treatment with any of the Insuman® presentations listed within, they should be moved to a suitable alternative treatment over the coming months under the supervision of their prescribing clinician.

All the Insuman® presentations listed can continue to be used by your patients, prior to the dates outlined above, until they are able to transition to an alternative treatment.

Sanofi remains committed to people living with diabetes in the UK and their clinicians. We continue to act on this commitment through our medicines, services, technologies, and support for the wider community.

Human Insulins in the UK:
The following human insulin presentations are marketed in the UK[2]:

Manufacturer	Type	Product
Eli Lilly and Company Ltd	Insulin soluble human	Humulin S 100units/ml solution for injection 10ml vials
Novo Nordisk Ltd	Insulin soluble human	Actrapid 100units/ml solution for injection 10ml vials
Eli Lilly and Company Ltd	Insulin soluble human	Humulin S 100units/ml solution for injection 3ml cartridge
Eli Lilly and Company Ltd	Insulin isophane human	Humulin I 100units/ml suspension for injection 10ml vials
Novo Nordisk Ltd	Insulin isophane human	Insulatard 100units/ml suspension for injection 10ml vials
Eli Lilly and Company Ltd	Insulin isophane human	Humulin I 100units/ml suspension for injection 3ml cartridges
Novo Nordisk Ltd	Insulin isophane human	Insulatard Penfill 100units/ml suspension for injection 3ml cartridges
Eli Lilly and Company Ltd	Insulin isophane human	Humulin I KwikPen 100units/ml suspension for injection 3ml pre-filled pens
Eli Lilly and Company Ltd	Insulin biphasic isophane human	Humulin M3 100units/ml suspension for injection 10ml vials
Eli Lilly and Company Ltd	Insulin biphasic isophane human	Humulin M3 100units/ml suspension for injection 3ml cartridges
Eli Lilly and Company Ltd	Insulin biphasic isophane human	Humulin M3 KwikPen 100units/ml suspension for injection 3ml pre-filled pens

If you require any further information in relation to this, please contact:
Medical Information at Sanofi, 410 Thames Valley Park Drive, Reading, RG6 1PT, UK

- Tel: +44 (0) 800 035 2525
- Email: uk-medicalinformation@sanofi.com

Registered in England and Wales as Aventis Pharma Limited Company No. 01535640 ▪ T: 01183 543 000 ▪ F: 0800 471 8627
Registered Office: 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
www.sanofi.co.uk

For questions relating to ordering, please contact:

- **Sanofi Customer Services** Tel: +44 (0) 800 854 430 (Mon-Fri 9am – 5pm).

Call for reporting

Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card Scheme.

Please report:

- all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason
- all suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼

It is easiest and quickest to report ADRs online via the Yellow Card website - https://yellowcard.mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store.

Alternatively, prepaid Yellow Cards for reporting are available:

- by writing to FREEPOST YELLOW CARD (no other address details necessary)
- by emailing yellowcard@mhra.gov.uk
- at the back of the British National Formulary (BNF)
- by telephoning the Commission on Human Medicines (CHM) free phone line. Tel: 0800-731-6789
- by downloading and printing a form from the Yellow Card website (see link above)

Suspected adverse reactions can also be reported to Sanofi. Tel: 0800 0902314. Email: UKdrugsafety@sanofi.com.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, and product brand name.

Yours Sincerely,

Ross Murphy
Portfolio Strategy Manager, General Medicines Foundation UK & Ireland

References:

1. Longitudinal Patient Data, IQVIA Ltd, incorporating data derived from THIN, A Cegedim Database, (Data on file) Date accessed: Sept 2022
2. British National Formulary https://bnf.nice.org.uk/ accessed 14/12/2022

Registered in England and Wales as Aventis Pharma Limited Company No. 01535640 ▪ T: 01183 543 000 ▪ F: 0800 471 8627
Registered Office: 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
www.sanofi.co.uk